LGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults wit...

por Vinitsky, Anna, Chiang, Jason, Bag, Asim K, Campagne, Olivia, Stewart, Clinton F, Dunphy, Paige, Shulkin, Barry, Li, Qian, Lin, Tong, Hoehn, Mary Ellen, Johnson, Jason N, Towbin, Jeffrey A, Khan, Raja, Tatevossian, Ruth G, Armstrong, Gregory T, Potter, Brian, Conklin, Heather, Shearer, Todd, Scott, Susan, Robinson, Giles W
Publicado 2022